It has been shown in phase II studies, that the extent of increase in IL-6 in the plasma during treatment was associated with an inferior outcome in patients with rectal and ovarian cancer after bevacizumab and chemoradiation treatment65, and with an inferior outcome in patients with advanced hepatocellular carcinoma after sunitinib therapy66. This evidence concerns the gene IL6 and ovarian carcinoma.